Albert David Limited
Albert David Limited (ALBERTDAVD) financial statements and selected valuation metrics from NSE/BSE exchange filings through 30 June 2026.
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
albertdavidindia.com(opens the company website in a new tab)Key metrics
Price as of 2026-09-03
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Mar 2025 | Jun 2025 | Sept 2025 |
|---|---|---|---|
| Sales | 75 Cr | 71 Cr | 87 Cr |
| Operating expenses (approx.) | 80 Cr | 81 Cr | 85 Cr |
| EBITDA | -5 Cr | -11 Cr | 3 Cr |
| OPM % | -6.3% | -15.1% | 2.9% |
| Other income | -5 Cr | 22 Cr | -2 Cr |
| Interest | 0.13 Cr | 0.55 Cr | 0.75 Cr |
| Depreciation | 2 Cr | 2 Cr | 2 Cr |
| Profit before tax | -12 Cr | 8 Cr | -3 Cr |
| Tax % | 12.5% | 5.9% | -27.9% |
| Net profit | -10 Cr | 8 Cr | -3 Cr |
| EPS (₹) | ₹-18.10 | ₹13.91 | ₹-5.79 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2025 | TTM |
|---|---|---|
| Sales | 346 Cr | Sign in for TTM |
| Operating expenses (approx.) | 343 Cr | Sign in for TTM |
| EBITDA | 3 Cr | Sign in for TTM |
| OPM % | 0.9% | Sign in for TTM |
| Other income | 30 Cr | Sign in for TTM |
| Interest | 0.41 Cr | Sign in for TTM |
| Depreciation | 7 Cr | Sign in for TTM |
| Profit before tax | 25 Cr | Sign in for TTM |
| Tax % | 31.8% | Sign in for TTM |
| Net profit | 17 Cr | Sign in for TTM |
| EPS (₹) | ₹30.14 | Sign in for TTM |
| Dividend payout % | 1.4% | Sign in for TTM |
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2025 |
|---|---|
| Equity capital | 6 Cr |
| Reserves | 387 Cr |
| Borrowings | 10 Cr |
| Other liabilities | 109 Cr |
| Total liabilities | 511 Cr |
| Fixed assets (net) | 98 Cr |
| CWIP | 2 Cr |
| Investments | 261 Cr |
| Loans & advances | 4 Cr |
| Inventories | 64 Cr |
| Trade receivables | 27 Cr |
| Cash & bank | 0.42 Cr |
| Other assets | 55 Cr |
| Total assets | 511 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2025 |
|---|---|
| Cash from operating activity | -28 Cr |
| Cash from investing | 23 Cr |
| Cash from financing | 0.11 Cr |
| Net cash flow | -5 Cr |
| Free cash flow (OCF − Capex) | -43 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2025 |
|---|---|
| ROCE % | 6.4% |
| ROE % | 4.4% |
| Debtor days | 29 |
| Inventory days | 332 |
| Days payable | 195 |
| Cash conversion cycle | 166 |
| Debt / equity | 0.03 |
| Current ratio | 3.40 |
| Net debt / EBITDA | 3.18 |
Compare with peers
Loading peers…